Results 61 to 70 of about 112,622 (301)

Modulating NPC1L1 to Potentiate PARP Inhibitor-Induced Ferroptosis and Immune Response in Triple-Negative Breast Cancer

Pharmaceutics
Background/Objectives: Poly (ADP-ribose) polymerase (PARP) inhibitors have shown significant efficacy in treating BRCA-mutated cancers; however, a significant proportion of patients fail to respond.
Ge Li, Yuxia Yuan, Xinhua Wu, Lixian Wu
doaj   +1 more source

A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer

Сибирский онкологический журнал, 2022
Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert, I. A. Kolomiets, Y. A. Fesik, A. A. Ivanova, N. V. Yunusova, О. N. Churuksaeva   +5 more
doaj   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core  

BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. [PDF]

, 2016
The proteasome inhibitor MLN9708 is an orally administered drug that is hydrolyzed into its active form, MLN2238 (ixazomib). Compared with Bortezomib, MLN2238 has a shorter proteasome dissociation half-life and a lower incidence and severity of ...
Barkhouse, Darryll, Li, Guichao, Lu, Bo, Wan, Juefeng, Xiao, Sheng, Yang, Lifeng, Zhang, Zhen, Zhu, Ji   +7 more
core   +2 more sources

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsResearch in context

EBioMedicine, 2018
Background: PARP-1 plays a critical role in DNA damage repair and contributes to progression of cancer. To explore the role of PARP-1 in acute myeloid leukemia (AML), we analyzed the expression of PARP-1 in AML and its relation to the clinical prognosis.
Xia Li, Chenying Li, Jingrui Jin, Jinghan Wang, Jiansong Huang, Zhixin Ma, Xin Huang, Xiao He, Yile Zhou, Yu Xu, Mengxia Yu, Shujuan Huang, Xiao Yan, Fenglin Li, Jiajia Pan, Yungui Wang, Yongping Yu, Jie Jin   +17 more
doaj   +1 more source

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers

Frontiers in Pharmacology, 2022
PARP inhibitors have clinically demonstrated good antitumor activity in patients with BRCA mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated excellent inhibitory activity for both PARP1 and PARP2 enzymes.
Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu, Xiaoguang Chen, Xiaoguang Chen   +8 more
doaj   +1 more source

Exposure to the complement C5b-9 complex sensitizes 661W photoreceptor cells to both apoptosis and necroptosis. [PDF]

, 2015
The loss of photoreceptors is the defining characteristic of many retinal degenerative diseases, but the mechanisms that regulate photoreceptor cell death are not fully understood.
Francesca Cordeiro, M, Guo, L, Moss, SE, Shi, H, Stampoulis, D, Williams, JA   +5 more
core   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive BRCA-related breast cancer

Опухоли женской репродуктивной системы, 2022
PARP inhibitors. However, in clinical practice, despite the proven antitumor efficacy of drugs, acquired resistance to PARP inhibitors leads to difficulties in selecting further therapy due unknown resistance mechanisms and absence of algorithm of action.
A. I. Stukan, A. Yu. Goryainova, S. V. Sharov, O. A. Goncharova, Z. K. Khachmamuk, V. V. Durov   +5 more
doaj   +1 more source